首页> 外文OA文献 >No differences of immune activation and microbial translocation among HIV-infected children receiving combined antiretroviral therapy or protease inhibitor monotherapy.
【2h】

No differences of immune activation and microbial translocation among HIV-infected children receiving combined antiretroviral therapy or protease inhibitor monotherapy.

机译:在接受联合抗逆转录病毒疗法或蛋白酶抑制剂单一疗法的HIV感染儿童中,免疫激活和微生物易位没有差异。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This is a cross-sectional study of 15 aviremic chronic HIV-infected children revealing no differences in immune activation (IA; HLA-DRCD38 CD4 and CD8 T cells, and sCD14) and microbial translocation (MT; lipopolysaccharides (LPS) and 16S rDNA) among HIV-infected patients under combined antiretroviral treatment (cART; n = 10) or ritonavir-boosted protease inhibitor monotherapy (mtPI/rtv; n = 5). In both cases, IA and MT were lower in healthy control children (n = 32). This observational study suggests that ritonavir boosted protease inhibitor monotherapy (mtPI/rtv) is not associated with an increased state of IA or MT as compared with children receiving cART.
机译:这项横断面研究涉及15位非HIV慢性感染性儿童,显示免疫激活(IA; HLA-DRCD38 CD4和CD8 T细胞以及sCD14)和微生物易位(MT;脂多糖(LPS)和16S rDNA)没有差异接受抗逆转录病毒联合治疗(cART; n = 10)或利托那韦增强蛋白酶抑制剂单药治疗(mtPI / rtv; n = 5)的HIV感染患者。在这两种情况下,健康对照儿童的IA和MT均较低(n = 32)。这项观察性研究表明,与接受cART的儿童相比,利托那韦增强蛋白酶抑制剂单药治疗(mtPI / rtv)与IA或MT状态增加无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号